We’ve released new content on stem cell and cord blood markets that we are excited to share with you. Enjoy!
Pluristem is a clinical-stage biotechnology company that uses placental cells and a proprietary, 3D technology platform to develop cell therapies for a broad range of diseases. Pluristem Therapeutics specializes in placental-derived “PLX” cells, which are now being explored for applications that include critical limb ischemia (CLI), acute radiation syndrome (ARS), incomplete bone marrow engraftment, and more.
BioTime, Inc. and Asterias Biotherapeutics have entered into a “patent Cross-License Agreement for pluripotent stem cell-derived cell therapies and other potential uses that will provide the companies with the freedom to leverage a patent estate covering the therapeutic uses of pluripotent stem cell technology in their respective areas of focus.”
This is a guest post from RoosterBio, an innovative company that provides standardized stem cell product platforms to enable rapid clinical and commercial translation. A “Golden Age” is defined as a period of time in a field where “great tasks are accomplished.” As described by author Jon Rowley, we are now at the beginnings of the Golden Age of BioFabrication.
How Many Billions Are Spent Annually on Stem Cell Research? (The NIH Alone Spends $1.5B/Year)
Within the U.S., the National Institutes of Health (NIH) will invest an estimated $1.495 billion into stem cell research projects in 2016, spanning a wide range of fields from cell biology to electrical engineering. This is an increase from $1.391 billion in (actual) stem cell spending by the NIH in 2014 and $1.429 billion in (estimated) spending in 2015.
Minerva Biotechnologies announces a “major breakthrough for stem cell research and therapies – a simple method of inducing naïve state pluripotency in human stem cells.” While induced pluripotent stem cell (iPSC) techniques can reprogram an adult cell to a stem cell-like state, Minerva has discovered a “primitive growth factor, NME7-AB, that continues this reprogramming to an even earlier, embryonic-like point called the ‘naïve’ state.”
Cynata Therapeutics announced that it is receiving a R&D Tax Incentive refund of nearly $1 million for the 2014/2015 financial year. This major cash influx will assist the company with the upcoming clinical trial involving its Cymerus™ mesenchymal stem cell (MSC) product, CYP-001. Cynata’s Cymerus™ MSCs are derived from a single donation from a single donor, using induced pluripotent stem cells (iPSCs) as the source tissue.
Pluristem Therapeutics marks its first entry into the defense area. NIAID, a part of the U.S. National Institutes of Health (NIH), will initiate studies in large animals to evaluate dosing for Pluristem’s PLX-R18 as a medical countermeasure in the treatment of the hematologic components of Acute Radiation Syndrome (ARS).
In the past couple years, BioInformant has completely taken over the stem cell space. We dominate Google search for a massive number of stem cell terms, have the fastest growing stem cell account on Twitter, are a Top Influencer for Stem Cells on LinkedIn, sponsor stem cell industry conferences, release hundreds of articles on stem cell market news per year, and are a media expert for stem cell topics — most recently interviewed by the Wall Street Journal, Los Angeles Business Journal, and Xconomy. Unless you’re getting the same level of attention, check this out!
Want to be better informed than your competition? Get future stem cell industry updates.
BioInformant is the first and only market research firm to specialize exclusively in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, CBS News, Medical Ethics, and the Center for BioNetworking. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, and Becton Dickinson, BioInformant is your global leader in stem cell industry data.
Click here to view our global strategic reports for the stem cell and cord blood industry.